- About
- PsychU For You
- Topics
- Events
- Content
Psychopharmacology
APA Releases New Evidence-based Practice Guideline for Patients with Schizophrenia
Patients with schizophrenia should have documented, comprehensive, and person-centric treatment plans that include evidence-based nonpharmacologic and pharmacological treatments, according to a new practice guideline on the treatment of schizophrenia developed… Read MoreAbsence of Major Depression & Substance Use Disorder More Likely After Recovery From Eating Disorder
Those with an eating disorder (ED) frequently have psychiatric comorbidities; estimates range between 56% and 98%. Such comorbidities contribute to longer periods of illness and poorer outcomes. Major depression and… Read MoreFollow Up Q&A With Dr. Rowland – The Role Of Glutamate In Mood Disorders & Schizophrenia
During this question and answer session, Dr. Laura Rowland responds to unanswered questions from the PsychU webinar, “The Role of Glutamate in Mood Disorders & Schizophrenia,” which took place on… Read MoreFollow Up Q&A With Dr. Murrough – The Role Of Glutamate In Mood Disorders & Schizophrenia
During this question and answer session, Dr. James Murrough responds to unanswered questions from the PsychU webinar, “The Role of Glutamate in Mood Disorders & Schizophrenia,” which took place on… Read MoreLong-Acting Injectable Antipsychotics & How To Give An Intramuscular Injection
In an effort to support the growing number of professionals and diverse care settings where patients are able to receive a long-acting injectable (LAI) antipsychotic medication, nurse practitioners from the… Read MoreAmerican Foundation For Suicide Prevention Project 2025
Despite increasing efforts to raise awareness and prevention strategies across the globe, suicide rates are currently among the highest in history, with rates increasing over 30% in the United States… Read MoreCognitive Function & Neuroprotection In Schizophrenia
Schizophrenia has a worldwide prevalence of approximately 1%.1 Individuals living with the disease often experience neurocognitive deficits, as well as poor memory and attention, which are considered core symptoms for… Read MoreRecovery After Initial Schizophrenic Episode – Early Treatment Program (RAISE-ETP)
In this presentation, Stephen Murray, Pharm.D., MBA, Senior Medical Science Liaison for Otuska Pharmaceutical Development & Commercialization, Inc., shares insights from the Recovery After Initial Schizophrenic Episode – Early Treatment… Read More - PsychU For You
